Resources

Collective Service Documentation

Babcock University

Assessment of Knowledge, Perception and Readiness of Nigerians to Participate in the COVID-19 Vaccine Trial

Description

Developing an effective and safe COVID-19 vaccine is a global public health necessity in containing the pandemic, however, recruiting volunteers can be challenging in a clinical trial phase because of poor knowledge, negative perception, ethical issues and safety concerns.

This is a cross-sectional, web-based study conducted among the Nigerian populace from the 19th May to the 22nd of May, 2020. A 39-item survey instrument (questionnaire), which required about 7 minutes to complete, was developed using google forms via the Survey Monkey Platform, validated and the internet link distributed randomly to consenting participants from the six geopolitical zones of the country via social media. Descriptive statistics were carried out using Statistical Package for the Social Sciences Software-Version 25 (SPSS-25) to measure frequencies and percentages of the variables. Bivariate analysis was also conducted using chi-square and bivariate logistic regression, and statistical significance was determined by p<0.05 to identify predictors of Nigerians’ readiness to participate in COVID-19 vaccine trials.

Misinformation and disinformation strengthen vaccine scepticism and could undermine efforts to end the coronavirus pandemic. The outcome of this study further underscores the need for adequate public health enlightenment on the role of the vaccine in curbing the COVID-19 pandemic. This will ensure adequate deployment and acceptance of the vaccine when it finally arrives.


Additional languages

No items found

DETAILS

Publication

2020

Authors

Seyi Samson Enitan, Adesola Oyekunle Oyekale, Richard Yomi Akele, Kayode Abraham Olawuyi, Elisha Oluwatobi Olabisi, Amarachi Joy Nwankiti, Esther Ngozi Adejumo, and Comfort Bosede Enitan

Emergency

COVID-19

Language

English

Keywords

Nigeria, Vaccine hesitancy, risk perception, Behaviours, social science research, risk communication, FAQ, vaccines, COVID-19